Cynata Therapeutics Limited
ASX:CYP.AX
0.19 (AUD) • At close September 18, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) AUD.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 1.654 | 7.77 | 1.546 | 7.012 | 1.309 | 1.375 | 1.749 | 1.1 | 0.286 | 0.025 | 0.034 | 0.162 | 0.223 | 0.114 | 0 | 0.351 | 0 |
Cost of Revenue
| 0.281 | 0.28 | 0.28 | 0.28 | 0.281 | 0.28 | 0.28 | 0.28 | 0.281 | 0 | 0 | 0.009 | 0.521 | 0.389 | 0.34 | 0.01 | 0.331 | 0 |
Gross Profit
| -0.281 | 1.374 | 7.49 | 1.266 | 6.731 | 1.029 | 1.095 | 1.469 | 0.819 | 0.286 | 0.025 | 0.025 | -0.359 | -0.166 | -0.226 | -0.01 | 0.02 | 0 |
Gross Profit Ratio
| 0 | 0.831 | 0.964 | 0.819 | 0.96 | 0.786 | 0.796 | 0.84 | 0.745 | 1 | 1 | 0.744 | -2.21 | -0.747 | -1.984 | 0 | 0.057 | 0 |
Reseach & Development Expenses
| 8.681 | 12.394 | 8.825 | 3.778 | 5.92 | 5.652 | 3.221 | 3.473 | 4.155 | 1.92 | 0.503 | 0.091 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 0 | 3.176 | 3.994 | 4.224 | 2.467 | 2.635 | 2.454 | 2.465 | 1.615 | 1.836 | 2.491 | 0.697 | 0.909 | 2.474 | 1.836 | 0.409 | 1.15 | 0 |
Selling & Marketing Expenses
| 0 | 0.056 | 0.066 | 0.27 | 0.473 | 0.581 | 0.176 | 0.115 | 0.131 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 3.584 | 3.868 | 4.733 | 5.022 | 4.09 | 4.129 | 2.631 | 2.58 | 1.746 | 1.836 | 2.491 | 0.697 | 0.909 | 2.474 | 1.836 | 0.409 | 1.15 | 0 |
Other Expenses
| 0 | 1.912 | 6.938 | 1.298 | -0.222 | 1.328 | 1.422 | 1.685 | 1.094 | 0.46 | 0.025 | 0.176 | 0.194 | 0.13 | 0.07 | 0.25 | 1.005 | 0 |
Operating Expenses
| 12.265 | 16.263 | 6.62 | 8.8 | 10.232 | 9.781 | 5.851 | 6.053 | 5.901 | 4.261 | 3.147 | 0.873 | 1.383 | 2.528 | 1.906 | 1.419 | 1.607 | 0 |
Operating Income
| -12.546 | -16.543 | -6.9 | -9.08 | -10.512 | -10.061 | -6.131 | -6.333 | -6.181 | -3.975 | -3.122 | -0.848 | -1.742 | -2.694 | -2.132 | -1.376 | -2.135 | 0 |
Operating Income Ratio
| 0 | -10 | -0.888 | -5.873 | -1.499 | -7.689 | -4.458 | -3.621 | -5.621 | -13.92 | -124.605 | -24.972 | -10.724 | -12.085 | -18.718 | 0 | -6.09 | 0 |
Total Other Income Expenses Net
| 0.485 | 0.611 | 0.622 | -0 | 4.363 | 0.28 | 0.236 | 0.03 | 0.309 | 0.46 | 0.025 | -0.104 | 0.194 | 0.13 | 0 | 0.252 | 0.1 | 0 |
Income Before Tax
| -12.06 | -15.932 | -6.278 | -9.081 | -6.15 | -9.781 | -5.895 | -6.302 | -5.872 | -3.712 | -3.04 | -0.916 | -1.542 | -2.565 | -2.116 | -1.101 | -1.487 | 0 |
Income Before Tax Ratio
| 0 | -9.63 | -0.808 | -5.874 | -0.877 | -7.474 | -4.287 | -3.604 | -5.34 | -12.998 | -121.305 | -26.961 | -9.494 | -11.505 | -18.582 | 0 | -4.241 | 0 |
Income Tax Expense
| -2.316 | -1.654 | -0.833 | -1.391 | -2.51 | -1.309 | -1.329 | -1.749 | -0.933 | -0.089 | -0.083 | -0.036 | 0.196 | 0.138 | 0.011 | -0.078 | 0.104 | 0 |
Net Income
| -9.745 | -14.277 | -5.445 | -7.69 | -3.639 | -8.472 | -4.566 | -4.554 | -4.939 | -3.712 | -3.04 | -0.916 | -1.542 | -2.565 | -2.116 | -1.101 | -1.487 | 0 |
Net Income Ratio
| 0 | -8.63 | -0.701 | -4.974 | -0.519 | -6.474 | -3.32 | -2.604 | -4.492 | -12.998 | -121.305 | -26.961 | -9.494 | -11.505 | -18.582 | 0 | -4.241 | 0 |
EPS
| -0.054 | -0.098 | -0.038 | -0.059 | -0.035 | -0.085 | -0.05 | -0.057 | -0.068 | -0.061 | -0.067 | -0.039 | -0.16 | -0.5 | -0.55 | -0.32 | -0.44 | 0 |
EPS Diluted
| -0.054 | -0.098 | -0.038 | -0.059 | -0.035 | -0.085 | -0.05 | -0.057 | -0.068 | -0.061 | -0.067 | -0.039 | -0.16 | -0.5 | -0.55 | -0.32 | -0.44 | 0 |
EBITDA
| -12.265 | -16.263 | -6.62 | -8.8 | -10.232 | -9.781 | -5.851 | -6.053 | -5.901 | -3.813 | -3.147 | -0.915 | -1.127 | -2.546 | -2.103 | -1.427 | -1.477 | 0 |
EBITDA Ratio
| 0 | -9.83 | -0.852 | -5.692 | -1.459 | -7.475 | -4.255 | -3.461 | -5.366 | -13.352 | -125.597 | -26.932 | -6.937 | -11.422 | -18.465 | 0 | -4.214 | 0 |